V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220019595 | 220008191 | 0.99 | 68 | Curative (C) | 2018-03-27 | 2018-03-27 | AML16 DA 3+10 | N | N | 220031111 | AML16 TRIAL |
| 220019596 | 220017900 | 1.69 | 45.6 | Curative (C) | 2017-02-09 | 2017-02-13 | IDARUBICIN + TRETINOIN | N | N | 220031113 | IDARUBICIN + TRETINOIN |
| 220019597 | 220008200 | 0 | 68.8 | Palliative (P) | 2017-12-15 | 2017-12-16 | ATG + Busulfan + Fludarabine | N | N | 220031142 | ATG + BUSULFAN + FLUDARABINE |
| 220019598 | 220008210 | 1.57 | 65.4 | Curative (C) | 2016-12-20 | 2016-12-20 | Cyclophosphamide TBI Allograft | 2 | N | 220031213 | CYCLOPHOSPHAMIDE |
| 220019599 | 220014481 | 1.59 | 0 | Curative (C) | null | 2018-09-17 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220031249 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220019600 | 220008222 | 1.79 | 98.4 | Curative (C) | 2019-04-21 | 2019-04-22 | RUXOLITINIB | 02 | null | 220031250 | RUXOLITINIB |
| 220019601 | 220014482 | null | 90 | Disease modification (D) | 2016-12-02 | 2017-04-20 | Idarubicin+Tretinoin Spanish Crse4 | null | null | 220031254 | IDARUBICIN + TRETINOIN |
| 220019602 | 220019830 | 1.65 | 65 | Curative (C) | null | 2014-06-09 | AML Int Guide ADE 8+3+5 (2) | N | N | 220031258 | ADE |
| 220019605 | 220008235 | 1.84 | 68 | Curative (C) | 2016-01-12 | 2016-01-17 | Methotrexate intrathecal | 2 | N | 220031299 | METHOTREXATE INTRATHECAL |
| 220019606 | 220008240 | 1.59 | 80.8 | Curative (C) | null | 2014-12-24 | Cyclophosphamide TBI Allograft | null | null | 220031302 | CYCLOPHOSPHAMIDE |
| 220019607 | 220008252 | 1.92 | null | Curative (C) | 2015-10-01 | 2015-10-01 | FLAG | N | N | 220031392 | FLAG |
| 220019609 | 220008263 | 1.08 | 55 | null | 2017-11-17 | 2017-12-26 | BOSUTINIB | null | null | 220031415 | BOSUTINIB |
| 220019610 | 220008271 | 1.62 | null | Curative (C) | 2014-06-23 | 2014-08-25 | Cyclophosphamide TBI Allograft | 02 | N | 220031435 | CYCLOPHOSPHAMIDE |
| 220019611 | 220008274 | null | 49.8 | Palliative (P) | 2016-01-11 | 2016-01-11 | BOSUTINIB | 2 | N | 220031441 | BOSUTINIB |
| 220019612 | 220008277 | 1.66 | null | Curative (C) | 2014-12-23 | 2014-12-26 | Cyclophosphamide TBI Allograft | N | N | 220031455 | CYCLOPHOSPHAMIDE |
| 220019613 | 220008281 | 1.66 | 75 | Curative (C) | 2013-12-31 | 2014-07-25 | Methotrexate intrathecal | N | N | 220031479 | METHOTREXATE INTRATHECAL |
| 220019614 | 220014507 | 1.78 | 65 | Curative (C) | 2014-09-26 | 2014-09-28 | RUXOLITINIB | 2 | N | 220031482 | RUXOLITINIB |
| 220019615 | 220008287 | null | 57 | Curative (C) | null | 2017-09-16 | AML Int Guide ADE 8+3+5 (2) | N | null | 220031491 | ADE |
| 220019616 | 220008305 | null | 86.8 | Curative (C) | null | 2016-04-10 | BOSUTINIB | null | N | 220031551 | BOSUTINIB |
| 220019617 | 220008310 | null | 63.5 | Curative (C) | 2013-12-26 | 2013-12-26 | Cyclophosphamide+Fludara+TBI Allo | N | N | 220031587 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220019618 | 220008318 | 1.69 | 88 | Curative (C) | 2014-08-28 | 2014-10-04 | Triple Intrathecal | N | N | 220031606 | TRIPLE INTRATHECAL |
| 220019619 | 220014520 | 1.75 | 113.8 | Disease modification (D) | 2012-12-01 | 2013-06-29 | Cyclophosphamide+Fludara+TBI Allo | N | N | 220031607 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220019620 | 220017933 | 1.91 | null | Curative (C) | 2019-01-19 | 2019-01-20 | ATG + Busulfan + Fludarabine | N | N | 220031612 | ATG + BUSULFAN + FLUDARABINE |
| 220019621 | 220008327 | null | 16.4 | Curative (C) | 2013-08-05 | 2015-06-29 | FLAG | 2 | N | 220031621 | FLAG |
| 220019622 | 220008332 | 1.79 | 87.8 | Disease modification (D) | null | 2018-03-20 | IDARUBICIN + TRETINOIN | 02 | N | 220031625 | IDARUBICIN + TRETINOIN |
| 220019624 | 220019843 | 1.77 | null | Curative (C) | 2016-01-02 | 2016-12-06 | AML16 Low Dose Cytarabine | N | N | 220031681 | AML16 TRIAL |
| 220019625 | 220008345 | 1.8 | null | Curative (C) | 2013-05-16 | 2013-06-23 | ATG + Busulfan + Fludarabine | N | N | 220031687 | ATG + BUSULFAN + FLUDARABINE |
| 220019626 | 220008352 | 1.58 | 84 | Curative (C) | 2017-09-20 | 2017-09-20 | ATG + Busulfan + Fludarabine | N | N | 220031700 | ATG + BUSULFAN + FLUDARABINE |
| 220019627 | 220008354 | null | 18.3 | Disease modification (D) | 2016-12-19 | 2017-04-06 | Cyclophosphamide+Fludara+TBI Allo | N | N | 220031720 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220019628 | 220017941 | 1.63 | 83.45 | Not known (9) | 2013-11-01 | 2013-11-08 | Idarubicin+Tretinoin Spanish Crse1 | N | N | 220031735 | IDARUBICIN + TRETINOIN |
| 220019629 | 220008362 | 1.75 | null | Curative (C) | 2014-07-23 | 2014-07-23 | AML16 DA 2+5 | 2 | N | 220031736 | AML16 TRIAL |
| 220019631 | 220008364 | 1.03 | 29 | Curative (C) | 2015-04-12 | 2015-04-12 | BOSUTINIB | N | N | 220031746 | BOSUTINIB |
| 220019632 | 220014541 | 1.72 | 89.6 | Curative (C) | null | 2014-05-17 | BOSUTINIB | N | null | 220031749 | BOSUTINIB |
| 220019633 | 220014542 | 1.64 | 54 | Palliative (P) | 2016-10-06 | 2016-10-07 | BOSUTINIB | 2 | N | 220031774 | BOSUTINIB |
| 220019634 | 220008371 | 1.49 | 75 | Curative (C) | null | 2014-08-05 | Triple Intrathecal | N | N | 220031784 | TRIPLE INTRATHECAL |
| 220019635 | 220008375 | 1.6 | 56 | Curative (C) | 2013-06-24 | 2013-06-25 | Cyclophosphamide + Fludarabine IV | N | N | 220031792 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220019636 | 220008377 | 1.63 | null | Disease modification (D) | 2016-07-26 | 2016-07-26 | Idarubicin+Tretinoin Spanish Crse2 | N | N | 220031796 | IDARUBICIN + TRETINOIN |
| 220019637 | 220008379 | 1.65 | 75.4 | Disease modification (D) | 2018-10-28 | 2018-10-28 | AML Int Guide ADE 8+3+5 (2) | Y | null | 220031797 | ADE |
| 220019639 | 220008389 | 1.63 | null | Curative (C) | 2018-10-18 | 2019-01-13 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220031813 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220019641 | 220017949 | null | 113.8 | Curative (C) | 2014-02-06 | 2014-02-10 | BOSUTINIB | N | N | 220031821 | BOSUTINIB |
| 220019642 | 220014551 | 1.85 | 55.2 | Curative (C) | 2018-07-14 | 2018-07-14 | BOSUTINIB | N | N | 220031869 | BOSUTINIB |
| 220019643 | 220008400 | null | 87.5 | Curative (C) | 2017-02-03 | 2017-08-07 | Methotrexate intrathecal | 99 | N | 220031880 | METHOTREXATE INTRATHECAL |
| 220019644 | 220008403 | 1.75 | 65 | Curative (C) | 2018-07-17 | 2018-08-31 | Cyclophosphamide + Fludarabine IV | 02 | N | 220031895 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220019645 | 220008404 | null | 63.9 | null | null | 2016-01-31 | Cyclophosphamide TBI Allograft | N | null | 220031901 | CYCLOPHOSPHAMIDE |
| 220019646 | 220008409 | 1.56 | 56.7 | Curative (C) | 2013-06-30 | 2013-12-04 | Methotrexate intrathecal | N | N | 220031924 | METHOTREXATE INTRATHECAL |
| 220019647 | 220008414 | null | 15.3 | Curative (C) | 2016-04-01 | 2016-04-02 | IDARUBICIN + TRETINOIN | Y | N | 220031935 | IDARUBICIN + TRETINOIN |
| 220019650 | 220008418 | 1.52 | 77.8 | Curative (C) | 2016-12-25 | 2017-03-10 | Cyclophosphamide TBI Allograft | N | N | 220031947 | CYCLOPHOSPHAMIDE |
| 220019651 | 220014564 | 1.65 | null | null | 2014-10-08 | 2014-10-18 | Methotrexate intrathecal | N | null | 220031962 | METHOTREXATE INTRATHECAL |
| 220019652 | 220022105 | 1.68 | 74.2 | Curative (C) | null | 2018-01-27 | AML Int Guide ADE 8+3+5 (2) | 02 | N | 220031971 | ADE |
| 220019653 | 220008428 | 1.75 | 84.6 | Curative (C) | 2015-12-21 | 2016-02-06 | AML16 DA 3+8 | 2 | N | 220031998 | AML16 TRIAL |